de Górgolas M, Avilés P, Verdejo C, Fernández Guerrero M L
Department of Medicine, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Spain.
Antimicrob Agents Chemother. 1995 Apr;39(4):953-7. doi: 10.1128/AAC.39.4.953.
Using two strains of Staphylococcus aureus, one susceptible and one heterogeneously resistant to methicillin, for which MICs and MBCs of trimethoprim-sulfamethoxazole (TMP-SMX) were 0.06 and 0.06 micrograms/ml and 0.06 and 0.25 microgram/ml, respectively (concentrations are those of TMP), we studied the efficacies of TMP-SMX and cloxacillin, teicoplanin, and vancomycin for treatment of experimental staphylococcal endocarditis. Rabbits were treated with dosages of TMP-SMX selected to achieve concentrations in serum equivalent to that obtained in humans treated for Pneumocystis carinii pneumonia. The overall mortality rate of rabbits treated with TMP-SMX was 84% at day 3, not different from that of the control groups (P > 0.1). No sterile vegetations were observed to be present in control groups or in animals treated with TMP-SMX. However, 26, 60, and 75% of rabbits treated with teicoplanin, cloxacillin, and vancomycin, respectively, showed sterile vegetations. For methicillin-susceptible S. aureus (MSSA), the mean vegetation counts were not significantly different between the control group and the group treated with TMP-SMX (P > 0.1). For methicillin-resistant S. aureus (MRSA), treatment with TMP-SMX was more effective than no therapy, decreasing the number of organisms in vegetations (P < 0.01). For both strains, therapy with cloxacillin and therapy with teicoplanin or vancomycin were significantly more effective than therapy with TMP-SMX. Despite high concentrations of teicoplanin in serum which exceeded MBCs for staphylococci more than 50 times at the peak and 10 times at the trough, therapy with cloxacillin or vancomycin was superior to therapy with teicoplanin against both MSSA and MRSA. These data do not support the use of TMP-SMX in treatment of endocarditis and other severe staphylococcal infections with high bacterial counts.
使用两株金黄色葡萄球菌,一株对甲氧西林敏感,另一株对甲氧西林呈异质性耐药,其甲氧苄啶 - 磺胺甲恶唑(TMP - SMX)的最低抑菌浓度(MIC)和最低杀菌浓度(MBC)分别为0.06和0.06微克/毫升以及0.06和0.25微克/毫升(浓度为TMP的浓度),我们研究了TMP - SMX以及氯唑西林、替考拉宁和万古霉素治疗实验性葡萄球菌性心内膜炎的疗效。给兔子使用的TMP - SMX剂量旨在使其血清浓度达到治疗卡氏肺孢子虫肺炎的人类患者所获得的浓度。在第3天,接受TMP - SMX治疗的兔子总体死亡率为84%,与对照组无差异(P>0.1)。在对照组或接受TMP - SMX治疗的动物中均未观察到无菌赘生物。然而,分别接受替考拉宁、氯唑西林和万古霉素治疗的兔子中,有26%、60%和75%出现了无菌赘生物。对于甲氧西林敏感金黄色葡萄球菌(MSSA),对照组和接受TMP - SMX治疗组的平均赘生物计数无显著差异(P>0.1)。对于耐甲氧西林金黄色葡萄球菌(MRSA),TMP - SMX治疗比不治疗更有效,可减少赘生物中的细菌数量(P<0.01)。对于这两种菌株,氯唑西林治疗以及替考拉宁或万古霉素治疗均比TMP - SMX治疗显著更有效。尽管血清中替考拉宁的高浓度在峰值时超过葡萄球菌MBC 50倍以上,在谷值时超过10倍,但氯唑西林或万古霉素治疗在针对MSSA和MRSA方面均优于替考拉宁治疗。这些数据不支持将TMP - SMX用于治疗心内膜炎和其他细菌数量高的严重葡萄球菌感染。